Table 3 Association between baseline characteristics and on-therapy grade 3/4 proteinuria

From: Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

 

Unadjusted (univariate) analysis

Adjusted (multivariable) analysis

 

HR

95% CI

P -value

HR

95% CI

P -value

Pre-existing proteinuria

3.26

1.81–5.87

<0.001

3.04

1.65–5.61

0.001

Age (per 10 years)

1.21

0.92–1.58

0.173

1.16

0.82–1.65

0.400

Male sex

0.99

0.53–1.86

0.977

0.91

0.45–1.86

0.796

Ethnicity (vs White)

      

 Asian

2.35

1.34–4.11

0.003

3.34

1.60–6.95

0.001

 Other

1.61

0.22–12.0

0.641

1.38

0.18–10.4

0.758

SBP (per 10 mm Hg)

1.22

0.99–1.50

0.065

1.14

0.91–1.43

0.267

BSA (per m2)

0.51

0.18–1.46

0.210

0.57

0.12–2.67

0.477

Diabetes

3.24

1.78–5.91

<0.001

2.04

1.03–4.00

0.040

eGFR (per 10 ml min−1)

1.00

0.91–1.11

0.957

1.07

0.93–1.22

0.349

Prior nephrectomy

0.67

0.34–1.34

0.256

0.81

0.38–1.72

0.588

Pazopanib (vs sunitinib)

1.02

0.57–1.83

0.942

0.98

0.54–1.79

0.950

Use of ASI

1.71

0.98–2.99

0.061

1.48

0.75–2.91

0.256

Use of other AHD

1.85

1.06–3.21

0.030

1.35

0.70–2.60

0.367

Use of nephrotoxic drug

1.57

0.88–2.81

0.128

1.53

0.81–2.89

0.188

  1. Abbreviations: AHD=antihypertensive drug; ASI=angiotensin system inhibitor; BSA=body surface area; CI=confidence interval; eGFR=estimated glomerular filtration rate; HR=hazard ratio; SBP=systolic blood pressure.
  2. Note: multiple imputation estimates reported for unadjusted pre-existing proteinuria and BSA, and all adjusted covariates.
Back to article page